A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
- Conditions
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 273
- Registration Number
- NCT02040779
- Locations
- 🇺🇸
Teva Investigational Site 10962, Tallahassee, Florida, United States
🇺🇸Teva Investigational Site 10968, Rolla, Missouri, United States
🇺🇸Teva Investigational Site 12941, Missoula, Montana, United States
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1113
- Registration Number
- NCT02031640
- Locations
- 🇺🇸
Teva Investigational Site 10861, Los Angeles, California, United States
🇺🇸Teva Investigational Site 10832, Baltimore, Maryland, United States
🇺🇸Teva Investigational Site 10866, Seattle, Washington, United States
A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02030457
- Locations
- 🇺🇸
Teva Investigational Site, San Antonio, Texas, United States
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT02025556
- Locations
- 🇺🇸
Teva Investigational Site 135, Brockton, Massachusetts, United States
🇺🇸Teva Investigational Site 124, New Bedford, Massachusetts, United States
🇺🇸Teva Investigational Site 109, Watertown, Massachusetts, United States
Assessment of LBR-101 In Chronic Migraine
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02021773
- Locations
- 🇺🇸
Teva Investigational Site 161, Anaheim, California, United States
🇺🇸Teva Investigational Site 116, Fullerton, California, United States
🇺🇸Teva Investigational Site 108, Stanford, California, United States
Safety and Bioavailability of IV and SC LBR-101
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01991509
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Absolute Bioavailability of Reslizumab in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01990443
- Locations
- 🇺🇸
Teva Investigational Site 10567, Anaheim, California, United States
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT01975298
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT01940601
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT01922739
- Locations
- 🇺🇸
Teva Investigational Site 10426, Mobile, Alabama, United States
🇺🇸Teva Investigational Site 10425, Carmichael, California, United States
🇺🇸Teva Investigational Site 10370, Los Angeles, California, United States